Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CD19/BCMA CAR T-cells in R/R AIHA
NCT06920446Phase 1Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR T-cells in autoimmune hemolytic anemia (AIHA), sponsored by Zhejiang University. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 90 days and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT06920446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920446.